A Systematic Review of Vancomycin Dosing in Patients with Hematologic Malignancies or Neutropenia

References

• Matzke GR, Aronoff GR, Atkinson AJ, et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80(11):1122–1137. doi:10.1038/ki.2011.32221918498
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Takesue Y, Ohmagari N, et al. Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother. 2013;19(3):365–380. doi:10.1007/s10156-013-0599-423673472
   PubMed Web of Science ®Google Scholar
• Bilbao-Meseguer I, Rodriguez-Gascon A, Barrasa H, Isla A, Solinis MA. Augmented renal clearance in critically Ill patients: a systematic review. Clin Pharmacokinet. 2018;57(9):1107–1121. doi:10.1007/s40262-018-0636-729441476
   PubMed Web of Science ®Google Scholar
• Udy AA, Jarrett P, Lassig-Smith M, et al. Augmented renal clearance in traumatic brain injury: a single-center observational study of atrial natriuretic peptide, cardiac output, and creatinine clearance. J Neurotrauma. 2017;34(1):137–144. doi:10.1089/neu.2015.432827302851
   PubMed Web of Science ®Google Scholar
• Kim AJ, Lee JY, Choi SA, Shin WG. Comparison of the pharmacokinetics of vancomycin in neurosurgical and non-neurosurgical patients. Int J Antimicrob Agents. 2016;48(4):381–387. doi:10.1016/j.ijantimicag.2016.06.02227546217
   PubMed Web of Science ®Google Scholar
• Keng MK, Sekeres MA. Febrile neutropenia in hematologic malignancies. Curr Hematol Malig Rep. 2013;8(4):370–378. doi:10.1007/s11899-013-0171-423990311
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56–e93.21258094
   PubMed Web of Science ®Google Scholar
• Goulenok T, Fantin B. Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet. 2013;52(10):869–883. doi:10.1007/s40262-013-0086-123807657
   PubMed Web of Science ®Google Scholar
• Lortholary O, Lefort A, Tod M, Chomat AM, Darras-Joly C, Cordonnier C. Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia. Lancet Infect Dis. 2008;8(10):612–620. doi:10.1016/S1473-3099(08)70228-718922483
   PubMed Web of Science ®Google Scholar
• Ye ZK, Chen YL, Chen K, et al. Therapeutic drug monitoring of vancomycin: a guideline of the division of therapeutic drug monitoring, chinese pharmacological society. J Antimicrob Chemother. 2016;71(11):3020–3025. doi:10.1093/jac/dkw25427494905
   PubMed Web of Science ®Google Scholar
• Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82–98. doi:10.2146/ajhp08043419106348
   PubMedGoogle Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.100009719621072
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Cochrane Collaboration; 2011:1–8.
   Google Scholar
• Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed 511, 2020.
   Google Scholar
• Kanji S, Hayes M, Ling A, et al. Reporting guidelines for clinical pharmacokinetic studies: the ClinPK statement. Clin Pharmacokinet. 2015;54(7):783–795. doi:10.1007/s40262-015-0236-825637173
   PubMed Web of Science ®Google Scholar
• O’Donnell R. Audit of BMT antibiotic febrile neutropenia guidelines. Bone Marrow Transplant. 2011;46:S433–S434.
   Web of Science ®Google Scholar
• Luo C, Hussaini T, Lacaria K, Yeung J, Lau TT, Broady RC. Evaluation of a Once-Daily Vancomycin regimen in an outpatient leukemia/bone marrow transplant clinic (OD-VANCO Study). Can J Hosp Pharm. 2014;67(4):280–285. doi:10.4212/cjhp.v67i4.137225214659
   PubMedGoogle Scholar
• Donovan KA, Sklenicka J. Is a standard vancomycin dosing protocol appropriate to achieve therapeutic trough levels in adult neutropenic patients? Pharmacotherapy. 2012;32(10):e237–e238.
   Web of Science ®Google Scholar
• Vermis K, Steel E, Vandenbroucke J. Prevalence of augmented renal clearance in haematological patients and the impact on vancomycin dosing. J Oncol Pharm Pract. 2014;20(3):7.
   Google Scholar
• Ghehi MT, Rezaee S, Hayatshahi A, et al. Vancomycin pharmacokinetic parameters in patients undergoing Hematopoietic Stem Cell Transplantation (HSCT). Int J Hematol Oncol Stem Cell Res. 2013;7(4):1–9.
   PubMedGoogle Scholar
• Hochart C, Berthon C, Corm S, et al. Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia. Med Mal Infect. 2011;41(12):652–656. doi:10.1016/j.medmal.2011.09.01422056376
   PubMed Web of Science ®Google Scholar
• Vazin A, Japoni A, Shahbazi S, Davarpanah MA. Vancomycin utilization evaluation at hematology-oncology ward of a teaching hospital in iran. Iran J Pharm Res. 2012;11(1):163–170.24250438
   PubMed Web of Science ®Google Scholar
• Choi MH, Choe YH, Lee SG, Jeong SH, Kim JH. Neutropenia is independently associated with sub-therapeutic serum concentration of vancomycin. Clin Chim Acta. 2017;465:106–111. doi:10.1016/j.cca.2016.12.02128025029
   PubMed Web of Science ®Google Scholar
• Al-Kofide H, Zaghloul I, Al-Naim L. Pharmacokinetics of vancomycin in adult cancer patients. J Oncol Pharm Pract. 2010;16(4):245–250. doi:10.1177/107815520935584720015925
   PubMedGoogle Scholar
• Haeseker MB, Croes S, Neef C, Bruggeman CA, Stolk LM, Verbon A. Vancomycin dosing in neutropenic patients. PLoS One. 2014;9(11):e112008. doi:10.1371/journal.pone.011200825390637
   PubMed Web of Science ®Google Scholar
• Kureishi A, Jewesson PJ, Bartlett KH, Cole CD, Chow AW. Application of a modified bioassay for monitoring serum teicoplanin and vancomycin in febrile neutropenic patients. Antimicrob Agents Chemother. 1990;34(9):1642–1647. doi:10.1128/AAC.34.9.16422149492
   PubMed Web of Science ®Google Scholar
• Jarkowski IA, Forrest A, Sweeney RP, et al. Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population. J Oncol Pharm Pract. 2012;18(1):91–96. doi:10.1177/107815521140210721521799
   PubMedGoogle Scholar
• Le Normand Y, Milpied N, Kergueris MF, Harousseau JL. Pharmacokinetic parameters of vancomycin for therapeutic regimens in neutropenic adult patients. Int J Biomed Comput. 1994;36(1–2):121–125. doi:10.1016/0020-7101(94)90102-37927850
   PubMedGoogle Scholar
• Buelga DS,Fernandez de Gatta MM, Herrera EV, Dominguez-Gil A, Garcia MJ. Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies. Antimicrob Agents Chemother. 2005;49(12):4934–4941. doi:10.1128/AAC.49.12.4934-4941.200516304155
   PubMed Web of Science ®Google Scholar
• Hirai K, Ishii H, Shimoshikiryo T, et al. Augmented renal clearance in patients with febrile neutropenia is associated with increased risk for subtherapeutic concentrations of vancomycin. Ther Drug Monit. 2016;38(6):706–710. doi:10.1097/FTD.000000000000034627681114
   PubMed Web of Science ®Google Scholar
• Soto J, Alsar MJ, Chantal P, Sacristan JA. Correlation of vancomycin clearance and creatinine clearance: unreliability for predicting initial dosing in neutropenic haematological patients. J Antimicrob Chemother. 1993;32(6):920–922. doi:10.1093/jac/32.6.9208144443
   PubMed Web of Science ®Google Scholar
• Taghizadeh-Ghehi M, Rezaee S, Gholami K, Hadjibabaie M. Predictive performance of vancomycin population pharmacokinetic models in Iranian patients underwent hematopoietic stem cell transplantation. J Res Pharm Pract. 2015;4(3):129–134. doi:10.4103/2279-042X.16235726311080
   PubMedGoogle Scholar
• Fernandez de Gatta MM, Santos BD, Sanchez NA, Dominguez-Gil A, Garcia MJ. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis. Clin Pharmacokinet. 2009;48(4):273–280. doi:10.2165/00003088-200948040-0000519492872
   PubMed Web of Science ®Google Scholar
• Fernandez de Gatta MM, Calvo MV, Hernandez JM, Caballero D, San MJ, Dominguez-Gil A. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clin Pharmacol Ther. 1996;60(3):332–340. doi:10.1016/S0009-9236(96)90060-08841156
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Tokimatsu I, Morinaga Y, et al. A retrospective analysis to estimate target trough concentration of vancomycin for febrile neutropenia in patients with hematological malignancy. Clin Chim Acta. 2015;440:183–187. doi:10.1016/j.cca.2014.11.02725476135
   PubMed Web of Science ®Google Scholar
• Bury D, Ter Heine R, van de Garde E, et al. The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults. Eur J Clin Pharmacol. 2019;75(7):921–928. doi:10.1007/s00228-019-02657-630877327
   PubMed Web of Science ®Google Scholar
• Izumisawa T, Kaneko T, Soma M, et al. Augmented renal clearance of vancomycin in hematologic malignancy patients. Biol Pharm Bull. 2019;42(12):2089–2094. doi:10.1248/bpb.b19-0065231534058
   PubMed Web of Science ®Google Scholar
• Okada A, Kariya M, Irie K, et al. Population pharmacokinetics of vancomycin in patients undergoing allogeneic hematopoietic stem-cell transplantation. J Clin Pharmacol. 2018;58(9):1140–1149. doi:10.1002/jcph.110629762865
   PubMed Web of Science ®Google Scholar
• Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet. 1986;11(4):257–282. doi:10.2165/00003088-198611040-000013530582
   PubMed Web of Science ®Google Scholar
• Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1984;25(4):433–437. doi:10.1128/AAC.25.4.4336732213
   PubMed Web of Science ®Google Scholar
• Haeseker M, Croes S, Neef C, Bruggeman C, Stolk L, Verbon A. Evaluation of vancomycin prediction methods based on estimated creatinine clearance or trough levels. Ther Drug Monit. 2016;38(1):120–126. doi:10.1097/FTD.000000000000025026418699
   PubMed Web of Science ®Google Scholar
• Fernandez de Gatta MM, Fruns I, Dominguez-Gil A. Individualizing vancomycin dosing regimens: an evaluation of two pharmacokinetic dosing programs in critically ill patients. Pharmacotherapy. 1994;14(2):196–201.8197039
   PubMed Web of Science ®Google Scholar
• Krivoy N, Peleg S, Postovsky S, Ben AM. Pharmacokinetic analysis of vancomycin in steady state in pediatric cancer patients. Pediatr Hematol Oncol. 1998;15(4):333–338. doi:10.3109/088800198090140179658434
   PubMed Web of Science ®Google Scholar
• Omote S, Yano Y, Hashida T, et al. A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer patients based on routine trough monitoring data. Biol Pharm Bull. 2009;32(1):99–104. doi:10.1248/bpb.32.9919122288
   PubMed Web of Science ®Google Scholar
• Toro JJ, Diaz-Duque AE, Gass MJ, Haile DJ, Gushiken F. Acute renal injury and vancomycin levels in patients undergoing autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(3):S139. doi:10.1016/j.bbmt.2016.12.269
   Google Scholar
• Mae H, Ooi J, Takahashi S, et al. Early renal injury after myeloablative cord blood transplantation in adults. Leuk Lymphoma. 2008;49(3):538–542. doi:10.1080/1042819070182457718297532
   PubMed Web of Science ®Google Scholar